Papa Medical INC

Papa Medical Inc. reported a significant net loss of $0.8 million for the three months ended September 30, 2025, driven by a 26.1% revenue decrease and increased operating expenses.

Papa Medical Inc. announced significant revenue and net income growth for the six months ended June 30, 2025, driven by E-vapor sales and new products, despite a notable decrease in cash reserves.

Papa Medical Inc. is pursuing an initial public offering of 3.75 million Class A common shares at $4.00 per share, aiming to raise $12.8 million, while facing significant regulatory changes impacting a substantial portion of its Hemp cannabinoid E-vapors business.

Papa Medical Inc. is proceeding with its initial public offering of 1.5 million Class A common shares at $4.00 per share, aiming to raise $4.95 million, amidst significant regulatory changes impacting its core Delta-8 THC product line and recent declines in profitability.

Papa Medical Inc., a pioneering provider of Hemp dosing solutions, filed an S-1/A for its initial public offering of 1.25 million Class A common shares at an estimated US$4 per share, seeking Nasdaq listing.

Papa Medical Inc., a pioneering provider of end-to-end Hemp dosing solutions, has filed an amended S-1 registration statement for its initial public offering of 1,250,000 shares at an estimated price of US$4 per share, aiming to raise US$5 million before expenses for R&D, plant upgrades, and sales expansion.

Papa Medical Inc., an end-to-end Hemp dosing solution provider, filed an amended S-1 registration statement detailing its initial public offering of 1,250,000 Class A common shares at an estimated US$4.00 per share, showcasing significant revenue growth in Q1 2025 but facing substantial regulatory and concentration risks.

Papa Medical Inc., a cannabis dosing solutions provider, has filed for an initial public offering of its Class A common stock on the Nasdaq Capital Market.